IFNA1 and COVID-19: Interestingly, given that SARS-CoV-2 infection induces low type I and III IFN levels [163], the potential use of IFNs as a treatment strategy for COVID-19 or synthetic PRR agonists to increase the induction of IFN response are discussed and are currently under investigation [164].